Eisai and BMS partner to develop antibody drug conjugate for cancer
Eisai will get $650m from BMS and is also eligible for nearly $2.45bn in potential milestone payments.
Oncology
Debiopharm and Ubix join forces to develop new anti-cancer modality
The companies are combining their proprietary technologies to develop Antibody Degraducer Conjugates.
Umoja Biopharma raises $210m to advance next-gen cancer immunotherapy technology
The company is building an integrated cellular immunotherapy platform to reprogramme immune cells in vivo.
Novartis prostate cancer drug gets FDA breakthrough designation
The FDA breakthrough designation is based on positive results from the Phase III VISION study...
Umoja Biopharma raises $210m to develop cancer treatments
The funds will also be used to set up internal manufacturing capabilities to clinically develop...
HiFiBiO raises series D funds to advance immuno-oncology candidates
HiFiBiO Therapeutics plans to accelerate two immuno-oncology programmes and to validate its Drug Intelligent Science platform in clinical trials.
GSK and iTeos partner to develop antibody for cancer treatment
iTeos will receive an upfront payment of $625m and is eligible to get up to $1.45bn in potential milestone payments.
ARPA-H: Biden’s proposed government health agency hopes to cure cancer
The White House has requested $6.5bn of federal funding for an agency to investigate treatments for cancer and other diseases.
argenx to regain rights to cusatuzumab from Janssen’s Cilag
The decision to discontinue the partnership between Cilag International and argenx is based on Janssen’s review of all available data on cusatuzumab.
Bristol Myers faces $6.4bn lawsuit over cancer drug delay
The complaint claimed that Bristol Myers breached an agreement after failing to get FDA approval for Breyanzi by 31 December last year.
MorphoSys to acquire Constellation Pharmaceuticals for $1.7bn
Adding Constellation’s products to MorphoSys’ portfolio would expedite its growth strategy and expansion into the solid tumour sector.
